TMC Japan BioBridge to provide Japanese healthcare innovators path to enter US market

Texas Medical Center (TMC), in the US, in partnership with Japan-based organisations Mitsui Fudosan Co. and The National Cancer Center, Japan’s leader in cancer treatment, has announced the launch of the TMC Japan BioBridge and JACT (Japan-Accelerator Cancer Therapeutics and Medical Devices)—a strategic alliance that aims to advance cancer treatment by connecting Japanese innovators with Texas Medical Center experts and providing a pathway for US market expansion.

JACT will focus on three key areas throughout the programme: 1) milestone development and financial planning, where participants will receive guidance on developing product milestones and managing financial requirements to support their US market ambitions, 2) clinical and regulatory expertise, where participants will receive access to US-based key opinion leaders and mentors in clinical trial design, manufacturing, and regulatory strategy for streamlined US entry, and 3) strategic partnerships and market insights, where participants will be connected with venture investors, strategic partners, and US-based healthcare advisors to support successful commercialisation.

In 2016, TMC launched the organisation’s first BioBridge, designed to provide a focused and strategic pathway for international healthcare companies preparing for US market expansion. JACT will offer this structured process for oncology companies in Japan, starting with an initial programme period where participants will gain insights into the US healthcare system. From there, these companies will meet decision-makers from pharmaceutical companies, hospital systems, and investors, receiving expert feedback on preparing for US regulatory approvals.